- Home
- CRVO vs ICCC Comparison
CRVO vs ICCC Comparison
Compare CRVO & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVO
- ICCC
- Stock Information
- Founded
- CRVO 2001
- ICCC 1982
- Country
- CRVO United States
- ICCC United States
- Employees
- CRVO N/A
- ICCC N/A
- Industry
- CRVO Biotechnology: Pharmaceutical Preparations
- ICCC Biotechnology: Pharmaceutical Preparations
- Sector
- CRVO Health Care
- ICCC Health Care
- Exchange
- CRVO Nasdaq
- ICCC Nasdaq
- Market Cap
- CRVO 67.4M
- ICCC 57.4M
- IPO Year
- CRVO N/A
- ICCC 1987
- Fundamental
- Price
- CRVO $8.50
- ICCC $6.56
- Analyst Decision
- CRVO Strong Buy
- ICCC
- Analyst Count
- CRVO 6
- ICCC 0
- Target Price
- CRVO $19.17
- ICCC N/A
- AVG Volume (30 Days)
- CRVO 92.4K
- ICCC 15.6K
- Earning Date
- CRVO 11-11-2025
- ICCC 11-12-2025
- Dividend Yield
- CRVO N/A
- ICCC N/A
- EPS Growth
- CRVO N/A
- ICCC N/A
- EPS
- CRVO N/A
- ICCC 0.20
- Revenue
- CRVO $7,776,968.00
- ICCC $28,274,756.00
- Revenue This Year
- CRVO N/A
- ICCC N/A
- Revenue Next Year
- CRVO N/A
- ICCC N/A
- P/E Ratio
- CRVO N/A
- ICCC $31.65
- Revenue Growth
- CRVO N/A
- ICCC 21.75
- 52 Week Low
- CRVO $1.80
- ICCC $3.38
- 52 Week High
- CRVO $16.94
- ICCC $7.60
- Technical
- Relative Strength Index (RSI)
- CRVO 51.94
- ICCC 58.43
- Support Level
- CRVO $7.90
- ICCC $6.30
- Resistance Level
- CRVO $8.93
- ICCC $6.99
- Average True Range (ATR)
- CRVO 0.42
- ICCC 0.30
- MACD
- CRVO 0.06
- ICCC 0.06
- Stochastic Oscillator
- CRVO 84.30
- ICCC 69.06
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.